Copyright: ©Author(s) 2026.
World J Clin Oncol. Sep 24, 2026; 17(9): 122832
Published online Sep 24, 2026. doi: 10.5306/wjco.122832
Published online Sep 24, 2026. doi: 10.5306/wjco.122832
Figure 1 Expression of AKAP95, Cx43, SCFFBXL2, SCFFBXO31 CPSF5, and CPSF6 in lung cancer tissue cases.
A and B: Low and high expression of AKAP95, respectively, in both the cytoplasm and nucleus; C and D: Low and high expression of Cx43, respectively, in both the cytoplasm and nucleus; E and F: Low and high expression of SCFFBXL2, respectively, predominantly in the cytoplasm; G and H: Low and high expression of SCFFBXO31, respectively, predominantly in the cytoplasm; I and J: Moderate and high expression of CPSF5, respectively, primarily in the nucleus; K and L: Low and high expression of CPSF6, respectively, primarily in the nucleus. Scale bars: 30 μm.
- Citation: Deng ZF, Zhao L, Yuan Y, Li LK, Ge MY, Dou LD, Zhang JW, Wang D, Guo DB, An R, Zhang YX, Song B. Correlations of the expression of AKAP95, Cx43, CPSF5/6, SCFFBXL2 and SCFFBXO31 in lung cancer tissues. World J Clin Oncol 2026; 17(9): 122832
- URL: https://www.wjgnet.com/2218-4333/full/v17/i9/122832.htm
- DOI: https://dx.doi.org/10.5306/wjco.122832